BIOTECH firm Circassia has continued to climb following its turnaround deal last week with AstraZeneca.
The company acquired rights to sell two of Astra’s respiratory drugs in the US. Analysts at Stifel Nicolaus upgraded Circassia to a ‘buy’ rating.
Circassia turned to respiratory drugs after its cat allergy treatment failed clinical trials last year. It is paying AstraZeneca £185m for the rights, while Astra takes a 14pc stake.
Shares climbed 13pc, or 12p, to 104p.